Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer.

Robert M. Wenham,Joseph W. Leach,Sidney A. Scudder,B. R. Amin,Charles H. Pippitt,Alan N. Gordon,Nuwan Nanayakkara,E. Hurh,Daniel E. Stepan,Russell J. Schilder

Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer.

2010

Robert M. Wenham
Joseph W. Leach
Sidney A. Scudder
B. R. Amin
Charles H. Pippitt
Alan N. Gordon
Nuwan Nanayakkara
E. Hurh
Daniel E. Stepan
Russell J. Schilder

5049 Background: AMG 386 is an investigational peptide-Fc fusion protein that inhibits angiogenesis by preventing angiopoietin 1/2 interaction with the Tie2 receptor. We report on an ongoing, open-...

Keywords:

Pegylated Liposomal Doxorubicin
Pathology
Ovarian cancer
Topotecan
Medicine
Cancer research
Tie2 Receptor
Angiogenesis
Fusion protein
advanced ovarian cancer
Angiopoietin-1
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations